Presented at ACTS
October 26, 2020
The quality of initial cellular raw material has a large impact on cell and gene therapy manufacturing and final product performance. This presentation will discuss Discovery Life Sciences’ capability to provide high-quality cellular material for cell and gene therapy manufacturing by integrating in-house apheresis collections across 2,800+ recallable donors with immunophenotyping, high resolution NGS HLA typing, flow cytometry, immune cell isolation and culture services.
Ask Your Questions
Have a question related to this presentation? Submit this form and we will get you answers.